Anticonvulsant hypersensitivity syndrome: An update

Expert Opinion on Drug Safety

Volumn 11, Issue 5, 2012, Pages 767-778

  Knowles, Sandra R ^a   Dewhurst, Norman ^b   Shear, Neil H ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

adverse drug reaction; anticonvulsants; hypersensitivity syndrome; lamotrigine

Indexed keywords

CARBAMAZEPINE; CORTICOSTEROID; CREATININE; CYCLOSPORIN; EPOXIDE; FOSPHENYTOIN SODIUM; GLUTATHIONE; HLA A ANTIGEN; HLA B ANTIGEN; IMMUNOGLOBULIN; INFLIXIMAB; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

AGE DISTRIBUTION; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; BLOOD CELL COUNT; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRESS SYNDROME; DRUG CROSS REACTIVITY; DRUG EXPOSURE; ENZYME ACTIVITY; EPSTEIN BARR VIRUS INFECTION; ERYTHRODERMA; ETHNICITY; FEVER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HEALTH CARE COST; HERPES VIRUS INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDRATION; INCIDENCE; INTERSTITIAL PNEUMONIA; LIVER FUNCTION TEST; LYMPHOCYTE TRANSFORMATION TEST; PATCH TEST; PATHOGENESIS; PATIENT INFORMATION; PLASMAPHERESIS; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN BIOPSY; SKIN MANIFESTATION; SKULL IRRADIATION; STEVENS JOHNSON SYNDROME; URINALYSIS; VIREMIA; VIRUS REACTIVATION;

ADRENAL CORTEX HORMONES; ANTICONVULSANTS; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; DRUG MONITORING; HISTAMINE ANTAGONISTS; HUMANS; INCIDENCE; ORGAN SPECIFICITY; PATIENT EDUCATION AS TOPIC; PHARMACOVIGILANCE; SEVERITY OF ILLNESS INDEX;

EID: 84865513600     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.705828     Document Type: Review

References (128)

1. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999;21(6):489-501 (Pubitemid 30021105)
2. Chaiken BH, Goldberg BI, Segal JP. Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 1950;242(23):897-8
3. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988;82(6):1826-32 (Pubitemid 19054926)
4. Gogtay N, Bavdekar S, Kshirsagar N. Anticonvulsant hypersensitivity syndrome: a review. Expert Opin Drug Saf 2005;4:571-81 (Pubitemid 40723728)
5. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995;155(21):2285-90
6. Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998;39(Suppl 7):S3-7 (Pubitemid 28485581)
7. De Vriese AS, Philippe J, Van Renterghem DM, et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine 1995;74(3):144-51
8. Nagata T, Kawamura N, Motoyama T, et al. A case of hypersensitivity syndrome resembling Langerhans cell histiocytosis during phenobarbital prophylaxis for convulsion. Jpn J Clin Oncol 1992;22(6):421-7
9. Bocquet H, Bagot M, Roujeau J. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-7 (Pubitemid 27197964)
10. Merritt HH, Putnam TJ. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. JAMA 1938;111:1068-73
11. D'Orazio J. Oxcarbazepine-induced dru reaction with eosinophilia and systemic symptoms (DRESS). Clin Toxicol 2008;46:1093-4
12. Amante MF, Filippini AV, Cejas N, et al. Dress syndrome and fulminant hepatic failure induced by lamotrigine. Ann Hepatol 2009;8(1):75-7
13. Roquin G, Peres M, Lerolle N, et al. First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis. Ann Pharmacother 2010;44(12):1998-2000
14. Amante M, Filippini A, Cejas N, et al. DRESS syndrome and fulminant hepati failure induced by lamotrigine. Ann Hepatol 2009;8:75-7
15. Maniyar F, Rooney C, Lilly O, et al. Anticonvulsant hypersensitivity syndrom presenting as aseptic meningitis. J Neuro 2009;256:1190-1
16. Fujita Y, Hasegawa M, Nabeshima K, et al. Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome. Intern Med 2010;49:409-13
17. Albayrak F, Cerrah S, Albayrak A, et al. DRESS syndrome with fatal results induced by sodium valproate in a patien with brucellosis and a positive cytoplasmic antineutrophilic cytoplasmic antibody test result. Rheumatol Int 2010; Epub ahead of print
18. Morimoto T, Sato T, Matsuoka A, et al. Trimethoprim-sulfamethoxazole- induced hypersensitivity syndrome associated with reactivation of human herpesvirus-6. Intern Med 2006;45(2):101-5 (Pubitemid 43285897)
19. Hicks ME, Smith CL, Stein GE. Trimethoprim/sulfamethoxazole-induced hypersensitivity syndrome. Ann Pharmacother 1997;31(10):1259 (Pubitemid 27431077)
20. Prussick R, Shear NH. Dapsone hypersensitivity syndrome. J Am Acad Dermatol 1996;35(2 Pt 2):346-9 (Pubitemid 26257276)
21. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol 1996;132(8):934-9 (Pubitemid 26266936)
22. Zuliani E, Zwahlen H, Gilliet F, Marone C. Vancomycin-induced hypersensitivity reaction with acute renal failure: resolution following cyclosporine treatment. Clin Nephrol 2005;64(2):155-8 (Pubitemid 41079013)
23. Gupta AK, Porges AJ. Hypersensitivity syndrome reaction to oral terbinafine. Australas J Dermatol 1998;39(3):171-2 (Pubitemid 28374353)
24. Lanzafame M, Rovere P, De Checchi G, et al. Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy. Scand J Infect Dis 2001;33(6):475-6 (Pubitemid 32611431)
25. Michel F, Navellou JC, Ferraud D, et al. DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis. Joint Bone Spine 2005;72(1):82-5 (Pubitemid 40169972)
26. Ghislain PD, Bodarwe AD, Vanderdonckt O, et al. Drug-induced eosinophilia and multisystemic failure with positive patch-test reaction to spironolactone: DRESS syndrome. Acta Derm Venereol 2004;84(1):65-8 (Pubitemid 38168367)
27. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993;27(3):337-43 (Pubitemid 23086961)
28. Bhargava P. Anticonvulsant hypersensitivity syndrome study of 60 cases. Indian J Dermatol Venereol Leprol 2001;67:317-19
29. Mahadeva U, Al-Mrayat M, Steer K, et al. Fatal phenytoin hypersensitivity syndrome. Postgrad Med J 1999;75(890):734-6
30. Quinones MD, Valero C, Salcedo M, et al. Phenytoin hypersensitivity syndrome with fatal evolution. Allergy 1999;54(1):83-4
31. Huang YL, Hong HS, Wang ZW, et al. Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis. J Am Acad Dermatol 2003;49(2):316-19
32. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005;209(2):123-9
33. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49(2):542-6 (Pubitemid 27368898)
34. Romero Maldonado N, Sendra Tello J, Raboso Garcia-Baquero E, Harto Castano A. Anticonvulsant hypersensitivity syndrome with fatal outcome. Eur J Dermatol 2002;12(5):503-5 (Pubitemid 35205149)
35. Metro G, Pino S, Pellegrini D, et al. Brain radiotherapy during treatment with anticonvulsant therapy as a trigger for toxic epidermal necrolysis. Anticancer Res 2007;27(2):1167-9 (Pubitemid 46587036)
36. Aguiar D, Pazo R, Duran I, et al. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol 2004;66(3):345-50 (Pubitemid 38258350)
37. Bessmertny O, Hatton RC, Gonzalez-Peralta RP. Antiepileptic hypersensitivity syndrome in children. Ann Pharmacother 2001;35(5):533-8 (Pubitemid 32428125)
38. Newell BD, Moinfar M, Mancini AJ, et al. Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS). Pediatr Dermatol 2009;26(5):536-46
39. Levy RM, Bredesen DE. Central nervous system dysfunction in acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr 1988;1(1):41-64 (Pubitemid 19128451)
40. Wong MC, Suite ND, Labar DR. Seizures in human immunodeficiency virus infection. Arch Neurol 1990;47(6):640-2 (Pubitemid 20183570)
41. Holtzman DM, Kaku DA, So YT. New-onset seizures associated with human immunodeficiency virus infection: causation and clinical features in 100 cases. Am J Med 1989;87(2):173-7 (Pubitemid 19201638)
42. Shapiro L, Shear N. Black race may predict increased severe cutaneous adverse reactions in phenytoin hypersensitivity syndrome reactions (abstract). Clin Invest Med 1998;21:S15
43. Lalic M, Cvejic J, Popovic J, et al. Lamotrigine and valproate pharmacokinetis interactions in epileptic patients. Eur J Drug Metab Pharmacokinet 2009;34:93-9
44. Dreesman A, Hoorens A, Hackimi-Idrissi S. Multiple organ dysfunction syndrome: infection or hypersensitivity reaction? Eur J Emerg Med 2010;17:228-9
45. Schlienger RG, Oh PI, Knowles SR, Shear NH. Quantifying the costs of serious adverse drug reactions to antiepileptic drugs. Epilepsia 1998;39(Suppl 7):S27-32 (Pubitemid 28485585)
46. Schlienger RK. Shear, N. Lamotrigine-associted anticonvulsant hypersensitivity syndrome. Neurology 1998;51:1172-5
47. Sierra NM, Garcia B, Marco J, et al. Cross Hypersensitivity syndrome between phenytoin and carbamazepine. Pharm World Sci 2005;27(3):170-4 (Pubitemid 41159965)
48. Seitz CS, Pfeuffer P, Raith P, et al. Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents. Ann Allergy Asthma Immunol 2006;97(5):698-702 (Pubitemid 44851471)
49. Spielberg S, Gordon G, Blake D, et al. Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol Exp Ther 1981;217:386-9 (Pubitemid 11112729)
50. Spielberg S, Gordon G, Blake D, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981;13:722-7 (Pubitemid 11062054)
51. Leeder JS, Riley RJ, Cook VA, Spielberg SP. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J Pharmacol Exp Ther 1992;263:360-7
52. Lu W, Uetrecht J. Possible bioactivation pathways of lamotrigine. Drug Metab Dispos 2007;35:1050-6 (Pubitemid 46956423)
53. Maggs J, Naisbitt D, Tettey J, et al. Metabolism of lamtorigine to a reactive arene oxide intermediate. Chem Res Toxicol 2000;13:1075-81
54. Pichler W. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683-93
55. Naisbitt D, Farrell J, Wong G, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003;111:1393-403 (Pubitemid 36683697)
56. Seishima M, Yamanaka S, Fujisawa T, et al. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol 2006;155:344-9 (Pubitemid 44050568)
57. Wong GAE, Shear NH. Is a drug alone sufficient to cause the drug hypersensitivity syndrome? Arch Dermatol 2004;140(2):226-30 (Pubitemid 38500337)
58. Eshki M, Allanore L, Musette P, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2009;145:67-72
59. Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007;157:934-40 (Pubitemid 47583515)
60. Shiohara T, Ijima M, Ikezawa Z, et al. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivation. Br J Dermatol 2007;156:1083-4 (Pubitemid 46642847)
61. Hara H, Kobayashi M, Yokoyama A, et al. Drug-induced hypersensitivity syndrome due to carbamazepine associated with reactivation ofhuman herpesvirus 7. Dermatology 2005;211:159-61 (Pubitemid 41160255)
62. Saida S, Yoshida A, Tanaka R, et al. A case of drug-induced hypersensitivity syndrome-like symptoms following HHV-6 encephalopathy. Allergol Int 2010;59:83-6
63. Oskay T, Karademir A, Erutrk O. Association of anticonvulsant hypersensitivity syndrome with herpesvirus 6, 7. Epilepsy Res 2006;70:27-40 (Pubitemid 43947513)
64. Chang JY, Kim SC. Anticonvulsant hypersensitivity syndrome associated with Epstein-Barr virus reactivation. Yonsei Med J 2007;48(2):317-20 (Pubitemid 46711765)
65. Scagni P, Morello M, Ramus MV, et al. Drug-induced hypersensivity syndrome associated with Epstein-Barr virus infection: a pediatric case report. Pediatr Dermatol 2009;26(2):229-31
66. Aihara M, Sugita Y, Takahashi S, et al. Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus. Br J Dermatol 2001;144(6):1231-4 (Pubitemid 34204218)
67. Asano Y, Kagawa H, Kano Y, et al. Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome. Arch Dermatol 2009;145(9):1030-6
68. Lin D, Tucker MJ, Rieder MJ. Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection. Ann Pharmacother 2006;40(9):1594-601 (Pubitemid 44330203)
69. Gennis MA, Vemuri R, Burns EA, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991;91(6):631-4
70. Calligaris L, Stocco G, De Iudicibus S, et al. Carbamazepine hypersensitivity syndrome triggered by a human herpes virus reactivation in a genetically predisposed patient. Int Arch Allergy Immunol 2009;149:173-7
71. Chung W, Hung S, Hong H, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486 (Pubitemid 38480527)
72. *1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48:1015-18 (Pubitemid 46763406)
73. Chung W, Hung S, Chen Y. Genetic predisposition of life-threatening antiepileptic-induced skin reactions. Expert Opin Drug Saf 2010;9:15-21
74. Hung S, Chung W, Jee S, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:297-306
75. Aihara M. Pharmacogenetics of cutaneous adverse drug reactions. J Dermatol 2011;38:246-54
76. Kashiwagi M, Aihara M, Takahashi Y, et al. HLA genotypes in carbamazepine induced severe cutaneous adverse drug response in Japanese patients. J Dermatol 2008;35:683-5
77. *3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-43
78. Hyson C, Sadler M. Cross-sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 1997;24:245-9 (Pubitemid 27400385)
79. Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-9 (Pubitemid 46763258)
80. Hirsch L, Arif H, Nahm E, et al. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008;71:1527-34
81. Murphy J, Mashman J, Miller J, et al. Suppression of carbamazepine- induced skin rash with prednisone. Neurology 1991;41:144-5
82. Son C, Lee C, Roh M, et al. Acute generalized exanthematous pustulosis as a manifestation of carbamazepine hypersensitivity syndrome. J Investig Allergol Clin Immunol 2008;18:461-4
83. Chen Y, Chiu H, Chu C. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010;146:1373-9
84. Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am 2009;29:481-501
85. Peyriere H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006;155:422-8 (Pubitemid 44050579)
86. Morkunas A, Miller M. Anticonvulsant hypersensitivity syndrome. Med Toxicol 1997;13:727-39 (Pubitemid 27432890)
87. Zaidi AN. Anticonvulsant hypersensitivity syndrome leading to reversible myocarditis. Can J Clin Pharmacol 2005;12(1):e33-40 (Pubitemid 43097181)
88. Arima M, Kanoh T, Yamasaki A, et al. Eosinophilic myocarditis associated with toxicodermia caused by phenobarbital. Jpn Circ J 1998;62(2):132-5
89. deMello DE, Liapis H, Jureidini S, et al. Cardiac localization of eosinophil-granule major basic protein in acute necrotizing myocarditis. N Engl J Med 1990;323(22):1542-5
90. Arsenovic N, Sheehan L, Clark D, et al. Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis. J Forensic Leg Med 2010;17(2):57-61
91. Bourgeois GP, Cafardi JA, Groysman V, et al. A review of DRESS-associated myocarditis. J Am Acad Dermatol 2011; Epub ahead of print
92. Do-Pham G, Charachon A, Duong T, et al. Drug reaction with eosinophilia and systemic symptoms and severe involvement of digestive tract: description of two cases. Br J Dermatol 2011;165:207-9
93. Balatsinou C, Milano A, Caldarella M, et al. Eosinophilic esophagitis is a component of the anticonvulsant hypersensitivity syndrome: description of two cases. Dig Liver Dis 2008;40:145-8
94. Pereira de Silva N, Piquioni P, Kochen S, Saidon P. Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs. Eur J Clin Pharmacol 2011;67(5):463-70
95. Ito S, Shioda M, Sasaki K, et al. Agranulocytosis following phenytoin-induced hypersensitivity syndrome. Brain Dev 2009;31:449-51
96. Gupta A, Eggo M, Uetrecht J, et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992;51:56-67
97. Brown R, Rother K, Artman H, et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch Dermatol 2009;145:63-6
98. Aota N, Hirahara K, Yea K. Systemic lupus erythematosus presenting with Kikuchi-Fujimoto's disease as a long-term sequela of drug-induced hypersensitivity syndrome. Dermatology 2009;218:275-7
99. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011;124:588-97
100. Neuman M, Malkiewicz I, Shear N. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin Biochem 2000;33:517-24 (Pubitemid 32011860)
101. Elzagallaai A, Knowles S, Rieder M, et al. Patch testing for the diagnosis of anticonvulsant hypersensivity syndrome: a systematic review. Drug Saf 2009;32:391-408
102. Elzagallaai AA, Knowles SR, Rieder MJ, et al. In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Mol Diagn Ther 2009;13(5):313-30
103. Bavdekar S, Muranjan M, Gogtay N, et al. Anticonvulsant hypersensitivity syndrome: lymphocyte toxicity assay for the confirmation of diagnosis and risk assessment. Ann Pharmacother 2004;38:1648-50 (Pubitemid 39297763)
104. Wu Y, Sanderson J, Farrell J, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006;118:233-41 (Pubitemid 43964854)
105. Beeler A, Engler O, Gerber B, Pichler W. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol 2006;117:455-62 (Pubitemid 43190160)
106. Allam J, Paus T, Reichel C, et al. DRESS syndrome associated with carbamazepine and phenytoin. Eur J Dermatol 2004;14:339-42 (Pubitemid 39222336)
107. Aouam K, Romdhane F, Loussaief C, et al. Hypersensitivity syndrome induced by anticonvulsants: possible cross-reactivity between carbamazepine and lamotrigine. J Clin Pharmacol 2009;49:1488-91
108. Voltolini S, Dignardi D, Minale P, et al. Phenobarbital-induced DiHS and ceftriaxone hypersensitivity reaction: a case of multiple drug allergy. Eur Ann Allergy Clin Immunol 2009;41:62-3
109. Ben Salem S, Slim R, Denguezli M, et al. A recurrent drug rash with eosinophilia and systemic symptoms. Pediatr Dermatol 2007;24:666-8 (Pubitemid 350173696)
110. Gaig P, Garcia-Orega P, Baltasar M, et al. Drug neosensitization during anticonvulsant hypersensitivity syndrome. J Investig Allergol Clin Immunol 2006;16:321-6 (Pubitemid 44580262)
111. Stewart MG, Duncan NO III, Franklin DJ, et al. Head and neck manifestations of erythema multiforme in children. Otolaryngol Head Neck Surg 1994;111(3 Pt 1):236-42 (Pubitemid 24299935)
112. Um SJ, Lee SK, Kim YH, et al. Clinical features of drug-induced hypersensitivity syndrome in 38 patients. J Investig allergol Clin Immunol 2010;20(7):556-62
113. Lens S, Crespo G, Carrion J, et al. Severe acute hepatitis in the DRESS syndrome: report of two cases. Ann Hepatol 2010;9:198-201
114. Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010;163(4):847-53
115. Harman KE, Morris SD, Higgins EM. Persistent anticonvulsant hypersensitivity syndrome responding to ciclosporin. Clin Exp Dermatol 2003;28(4):364-5 (Pubitemid 36801836)
116. Fischer M, Fiedler E, Marsch WC, et al. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002;146(4):707-9
117. Okumura A, Tsuge I, Kamachi Y, et al. Transient hypogammaglobulinemia after antiepileptic drug hypersensitivity. Pediatr Neurol 2007;36(5):342-4 (Pubitemid 46726964)
118. Mostella J, Pieroni R, Jones R, Finch CK. Anticonvulsant hypersensitivity syndrome: treatment with corticosteroids and intravenous immunoglobulin. South Med J 2004;97(3):319-21 (Pubitemid 38391299)
119. Straussberg R, Harel L, Ben-Amitai D, et al. Carbamazepine-induced Stevens-Johnson syndrome treated with IV steroids and IVIG. Pediatr Neurol 2000;22(3):231-3 (Pubitemid 30151167)
120. Prais D, Straussberg R, Amir J, et al. Treatment of anticonvulsant hypersensitivity syndrome with intravenous immunoglobulins and corticosteroids. J Child Neurol 2006;21(5):380-4 (Pubitemid 44057055)
121. Dredge DC, Parsons EC, Carter LP, et al. Anticonvulsant hypersensitivity syndrome treated with intravenous immunoglobulin. Pediatr Neurol 2010;43(1):65-9
122. Cumbo-Nacheli G, Weinberger J, Alkhalil M, et al. Anticonvulsant hypersensitivity syndrome: is there a role for immunomodulation? Epilepsia 2008;49(12):2108-12
123. Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40(3):458-61 (Pubitemid 29115308)
124. Chaidemenos GC, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997;36(3):218-21 (Pubitemid 27208324)
125. Smith H, Newton R. Adverse reactions to carbamazepine managed by desensitisation. Lancet 1985;1(8431):753 (Pubitemid 15104972)
126. Eames P. Adverse reactions to carbamazepine managed by desensitisation. Lancet 1989;1(8636):509-10 (Pubitemid 19063581)
127. Watts D, Bird J. Oxcarbazepine sensitivity treated by desensitisation. J Neurol Neurosurg Psychiatry 1991;54(4):376
128. Butte MJ, Dodson B, Dioun A. Pentobarbital desensitization in a 3-month-old child. Allergy Asthma Proc 2004;25(4):225-7